Curis

Curis, based in Lexington, MA, the United States, is a biotechnology company. Curis is a biotechnology company developing differentiated therapeutics for cancer patients, including an IRAK4 inhibitor in clinical development for haematologic malignancies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma. The largest, NCT03328078 (CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.